PHARMATICS LIMITED

Their core work

Pharmatics Limited is an Edinburgh-based technology SME that applies machine learning and data science to pharmaceutical and biomedical research challenges. Their work bridges computational methods and clinical application, with a particular focus on precision medicine — tailoring analysis to individual patient profiles rather than population averages. In EU research networks, they contribute industry expertise and real-world data science capabilities to academic-led PhD training programs, serving as the practitioner counterpart to university research teams. A secondary but growing focus is inflammatory disease, specifically arthritis, where they apply their analytical toolkit to understanding disease mechanisms and identifying therapeutic targets.

What they specialise in

How they've shifted over time

Both of Pharmatics' H2020 projects started in 2019, so a true chronological shift is not visible in this dataset — the keyword split is an artifact of how the two parallel projects are ordered rather than a genuine timeline change. That said, the two projects together reveal a deliberate dual focus: MLFPM2018 establishes their computational identity (ML, data science, precision medicine), while ArthritisHeal represents a disease-specific application of that toolkit to inflammatory conditions. The combination signals that Pharmatics is not a generic data science house — they appear to be concentrating their methods on specific therapeutic problems, with arthritis and inflammation as a defined vertical.

Pharmatics appears to be deepening a domain-specific ML strategy — applying computational precision medicine methods to chronic inflammatory diseases, which suggests future collaborations may emerge in rheumatology, immunology, or related drug discovery programs.

How they like to work

Pharmatics has participated exclusively as a third-party partner, never coordinating a project — a pattern typical of SMEs contributing specialist industry expertise to academic-led consortia. Both participations are in MSCA-ITN (Innovative Training Networks), where companies join as industry training hosts or technical mentors for doctoral researchers rather than as research leads. Despite only two projects, they are embedded in large, pan-European networks (31 unique partners), which reflects the structure of ITN consortia rather than an unusually broad individual network.

Through two MSCA-ITN projects, Pharmatics has connections with 31 unique consortium partners across 13 countries — a wide reach for a two-project SME, entirely attributable to the large multi-institution architecture of ITN networks. No dominant geographic cluster is evident from the data.

What sets them apart

Pharmatics occupies a rare niche as a small, specialist firm combining genuine pharmaceutical domain knowledge with machine learning and data science capability — a combination that most SMEs lack and most large pharma companies are too slow to deploy in collaborative research settings. Their consistent participation in MSCA training networks suggests they are valued as an industry mentor and real-world data science practitioner, offering PhD researchers hands-on exposure to applied computational methods. For consortium builders in health and digital health, they represent an accessible, focused industry partner without the overhead and IP complications of a large corporation.

Highlights from their portfolio

• MLFPM2018
  A five-year flagship training network (2019–2024) at the intersection of machine learning and precision medicine — among the most forward-looking MSCA-ITN themes of its cohort.
• ArthritisHeal
  Focuses on uncovering the molecular foundations of arthritic diseases with a direct therapeutic goal, combining basic science with a clear clinical application target.